197 472

Cited 0 times in

Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.

DC Field Value Language
dc.contributor.author김건민-
dc.contributor.author김기향-
dc.contributor.author김주훈-
dc.contributor.author김효송-
dc.contributor.author라선영-
dc.contributor.author박영년-
dc.contributor.author윤상현-
dc.contributor.author최준정-
dc.date.accessioned2015-04-23T17:39:05Z-
dc.date.available2015-04-23T17:39:05Z-
dc.date.issued2010-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/102869-
dc.description.abstractThe proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleNovel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSang Hyun Yoon-
dc.contributor.googleauthorKi Hyang Kim-
dc.contributor.googleauthorJunjeong Choi-
dc.contributor.googleauthorGun Min Kim-
dc.contributor.googleauthorJoo Hoon Kim-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorYoung Nyun Park-
dc.contributor.googleauthorSun Young Rha-
dc.identifier.doi10.4143/crt.2010.42.3.180-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00287-
dc.contributor.localIdA00342-
dc.contributor.localIdA00949-
dc.contributor.localIdA01202-
dc.contributor.localIdA01563-
dc.contributor.localIdA02561-
dc.contributor.localIdA04192-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid20948925-
dc.subject.keywordRenal cell carcinoma-
dc.subject.keywordRenal dialysis-
dc.subject.keywordSunitinib-
dc.contributor.alternativeNameKim, Gun Min-
dc.contributor.alternativeNameKim, Ki Hyang-
dc.contributor.alternativeNameKim, Joo Hoon-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNamePark, Young Nyun-
dc.contributor.alternativeNameYoon, Sang Hyun-
dc.contributor.alternativeNameChoi, Jun Jeong-
dc.contributor.affiliatedAuthorKim, Gun Min-
dc.contributor.affiliatedAuthorKim, Ki Hyang-
dc.contributor.affiliatedAuthorKim, Joo Hoon-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorPark, Young Nyun-
dc.contributor.affiliatedAuthorYoon, Sang Hyun-
dc.contributor.affiliatedAuthorChoi, Jun Jeong-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.citation.volume42-
dc.citation.number3-
dc.citation.startPage180-
dc.citation.endPage184-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.42(3) : 180-184, 2010-
dc.identifier.rimsid35058-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.